overview

OxThera is a biopharmaceutical company in late stage clinical development. The company develops products, based on its cell- and enzyme based proprietary technologies, for metabolic disorders of hyperoxaluria.

products

Oxabact^®: is an oral drug composed of lyophilized live Oxalobacter formigenes, an oxalate-degrading bacterium for the treatment of primary hyperoxaluria.

Oxazyme^®: is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for the treatment of enteric hyperoxaluria.